ArticleIndian journal of dermatology
Efficacy and Safety of Terbinafine 500 mg Once Daily in Patients with Dermatophytosis.
Article in Indian journal of dermatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05119712 (Terbinafine Treatment of Axial Spondyloarthropathy), which is not on this map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Terbinafine Treatment of Axial Spondyloarthropathy
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Mapping the Global Spread of T. indotineae: An Update on Antifungal Resistance, Mutations, and Strategies for Effective Management.Mycopathologia · 2024Pooled it
- Correlation ofAntimicrobial agents and chemotherapy · 2018Trial
- Efficacy of oral terbinafine versus itraconazole in treatment of dermatophytic infection of skin - A prospective, randomized comparative study.Indian journal of pharmacologyTrial
- Sensitivity of Dermatophytes to Terbinafine: World Experience and Recent Findings from Kazakhstan.Antibiotics (Basel, Switzerland) · 2026Article
- Trichophyton indotineae: Epidemiology, antifungal resistance and antifungal stewardship strategies.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Review
- Review
- Superficial Dermatophytosis across the World's Populations: Potential Benefits from Nanocarrier-Based Therapies and Rising Challenges.ACS omega · 2023Review
- Quality assurance of postharvest grapes against Botrytis cinerea by terbinafine.Natural products and bioprospecting · 2023Article
- Antifungal activity of alexidine dihydrochloride in a novel diabetic mouse model of dermatophytosis.Frontiers in cellular and infection microbiology · 2022Article
- Synergistic antifungal evaluation of over-the-counter antifungal creams with turmeric essential oil or Aloe vera gel against pathogenic fungi.BMC complementary medicine and therapies · 2021Article
- Expert Consensus on The Management of Dermatophytosis in India (ECTODERM India).BMC dermatology · 2018Article
- Oral Antifungal Therapy: Emerging Culprits of Cutaneous Adverse Drug Reactions.Indian dermatology online journalArticle
- Rational for Drug Dosimetry and Duration of Terbinafine in the Context of Recalcitrant Dermatophytosis: Is 500 mg Better than 250 mg OD or BD?Indian journal of dermatologyArticle
- Efficacy of Terbinafine and Itraconazole in Different Doses and in Combination in the Treatment of Tinea Infection: A Randomized Controlled Parallel Group Open Labeled Trial with Clinico-Mycological Correlation.Indian journal of dermatologyArticle
- The unprecedented epidemic-like scenario of dermatophytosis in India: II. Diagnostic methods and taxonomical aspects.Indian journal of dermatology, venereology and leprologyReview
- Repurposing Antifungal Drugs for Oral Cancer Treatment: Mechanistic Insights and Clinical Potential-A Narrative Review.Journal of International Society of Preventive & Community DentistryReview
- Therapeutic Updates on the Management of Tinea Corporis or Cruris in the Era ofIndian journal of dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDermatophytosis are the most common fungal infections globally. Terbinafine is considered to have good potency against dermatophytes, but resistance to terbinafine is on the rise.
objectiveThe objective of this study was to evaluate the efficacy and safety of terbinafine 500 mg given once daily in treatment of patients with superficial dermatophytosis. MATERIALS AND
methodsIt was a retrospective questionnaire-based survey. Each doctor was given survey questionnaire booklet containing survey forms. Clinical response was graded according to the improvement in the affected lesion. Mycological cure was defined as negative microscopy under potassium hydroxide examination and a negative culture in Sabouraud's dextrose agar. Patients were divided into three groups depending on the duration of therapy, Group A - terbinafine 500 mg for 2 weeks, Group B - terbinafine 500 mg for 4 weeks, and Group C - terbinafine 500 mg for 6 weeks.
resultsTotal 50 doctors completed the survey involving 440 patients. In Group A, out of 194 patients, 87% (
conclusionOur survey indicates that terbinafine in a dose of 500 mg given once daily was efficacious and safe in the treatment of patients with dermatophytosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.